Skip to content

Dementia foundations and person-centered support

Dementia Medications: Different Diseases, Different Treatment Questions

By KindredMind Editorial Team

There is no single category of medicine that treats every cause of dementia. Medication decisions depend on the underlying disease, symptoms, other health conditions, treatment goals and the person's preferences. Qualified clinicians should make those decisions with the person and their appropriate supports. This guide does not recommend a medicine, give doses or tell anyone to start, stop or change treatment.

Separate four different conversations

Swipe within the table to reach every column. Keyboard users can focus the table area and use the arrow keys.

Separate four different conversations
Treatment questionExamples or categoryEssential boundary
Symptoms affecting cognition or daily functionCholinesterase inhibitors and memantine in selected circumstancesThe underlying disease and current prescribing information determine appropriate use
Alzheimer's disease processesSelected anti-amyloid therapiesNot treatments for dementia generally; eligibility and monitoring are specialized
Associated symptomsIndividualized treatment of depression, sleep problems or severe distressInvestigate contributors and non-drug support; benefits and harms differ
Medicines that may worsen confusionReview of anticholinergic burden, sedating medicines and interactionsA medication review is not an instruction to stop a prescribed medicine

The Alzheimer's Association separates cognitive treatments from medicines for associated symptoms. A medicine's use for one disease should not be generalized to another. [1]

Medicines used for cognitive symptoms

Donepezil, rivastigmine and galantamine are cholinesterase inhibitors. Memantine acts through a different mechanism. These medicines have particular indications and safety considerations; they are not interchangeable and do not cure dementia. The relevant diagnosis, stage, other medicines, potential side effects and agreed goals all matter. [1]

Ask what improvement or stability the clinician hopes to assess, how adverse effects will be recognized and when treatment will be reviewed. Do not infer that a medicine is appropriate simply because another family uses it. Alzheimer's disease, Lewy body dementia, vascular dementia and FTD require distinct clinical consideration.

Alzheimer's-specific disease-modifying treatments

Lecanemab (Leqembi) and donanemab (Kisunla) are anti-amyloid treatments with U.S. FDA approvals for Alzheimer's disease. Their labels describe starting treatment in the mild cognitive impairment or mild dementia stage of Alzheimer's disease, with confirmation of amyloid pathology. They are not approved treatments for all causes of MCI or all dementias, and they do not restore lost abilities or cure Alzheimer's. [2][3]

These treatments can cause amyloid-related imaging abnormalities (ARIA), including brain swelling or bleeding. Serious and fatal events can occur. Specialist assessment, discussion of genetic and other risk factors, MRI monitoring and review of other medicines are important parts of their prescribing requirements. This page does not provide a dosing or monitoring schedule. The current label and treating specialist govern those details. [2][3]

Canada is a separate approval context. Health Canada's Leqembi decision describes conditional authorization with eligibility restricted to APOE ε4 noncarriers or heterozygotes and confirmed amyloid pathology. Its Kisunla decision also restricts the indicated population to APOE ε4 noncarriers or heterozygotes with early Alzheimer's disease and confirmed amyloid pathology. U.S. and Canadian labels must not be treated as identical. Authorization does not by itself establish local availability, public coverage or an individual's eligibility. [4][5]

Approval and safety statements were checked against the linked FDA label sources and Health Canada decisions during preview preparation on November 10, 2026. Every named medicine and approval statement must be reverified against current official information immediately before publication. This is not a complete formulary.

Associated symptoms need their own assessment

Pain, infection, depression, sleep disruption, sensory difficulty and medication effects can contribute to a change in functioning or distress. Treating the cause may be different from prescribing for the visible behavior. Non-drug support should reflect the person's routines, environment and preferences.

Some medicines used for severe associated symptoms have substantial risks. Antipsychotics carry serious warnings in older adults with dementia-related psychosis, and people with Lewy body dementia can have particular sensitivity. A specialist discussion is not replaced by a list of drug names. [1]

Prepare for a medication review

  • Bring the complete prescription, over-the-counter and supplement list.
  • Describe the change and its timing, including recent additions or changes.
  • Ask which condition and goal each medicine addresses.
  • Ask how benefit, side effects and interactions will be reviewed.
  • Ask whom to contact about a concern and what needs urgent help.

Do not independently stop a medicine because it appears on a “confusion” list. Abrupt changes can also cause harm. Sudden confusion needs prompt assessment; see delirium versus dementia. Person-centered care includes the person's priorities and informed participation, not a universal medication plan.

Sources

  1. Alzheimer's Association: Medications for memory, cognition and dementia-related behaviors.
  2. FDA: Leqembi prescribing information, 2026 label.
  3. FDA: Kisunla prescribing information, 2025 label.
  4. Health Canada: Leqembi regulatory decision summary.
  5. Health Canada: Kisunla regulatory decision summary.